FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Furlow Brenda S.
  2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP - General Counsel
(Last)
(First)
(Middle)
614 MCKINLEY PLACE NE
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2020
(Street)

MINNEAPOLIS, MN 55413
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/09/2020   M   9,079 A $ 108.49 13,390 D  
Common Stock 07/09/2020   S(1)   440 D $ 270.9659 (2) 12,950 D  
Common Stock 07/09/2020   S(1)   505 D $ 272.4778 (3) 12,445 D  
Common Stock 07/09/2020   S(1)   2,042 D $ 273.3317 (4) 10,403 D  
Common Stock 07/09/2020   S(1)   918 D $ 274.8048 (5) 9,485 D  
Common Stock 07/09/2020   S(1)   400 D $ 276.025 (6) 9,085 D  
Common Stock 07/09/2020   S(1)   1,954 D $ 277.2836 (7) 7,131 D  
Common Stock 07/09/2020   S(1)   2,746 D $ 278.061 (8) 4,385 D  
Common Stock 07/09/2020   S(1)   74 D $ 278.84 4,311 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 108.49 07/09/2020   M     9,079   (9) 08/07/2022 Common Stock 9,079 $ 0 921 D  
Restricted Stock Units (10)               (11)   (11) Common Stock 1,724   1,724 D  
Restricted Stock Units (10)               (12)   (12) Common Stock 1,969   1,969 D  
Restricted Stock Units (10)               (13)   (13) Common Stock 1,374   1,374 D  
Stock Option (Right to Buy) $ 106.59               (14) 08/18/2023 Common Stock 10,857   10,857 D  
Stock Options (Right to Buy) $ 190.41               (15) 08/07/2026 Common Stock 13,290   13,290 D  
Stock Options (Right to Buy) $ 177.32               (16) 08/08/2025 Common Stock 9,786   9,786 D  
Stock Options (Right to buy) $ 177.32               (13) 08/08/2025 Common Stock 7,339   7,339 D  
Stock Options (Right to Buy) $ 125.05               (17) 08/09/2024 Common Stock 12,670   12,670 D  
Stock Options (Right to buy) $ 125.05               (11) 08/09/2024 Common Stock 9,503   9,503 D  
Stock Options (Right to Buy) $ 106.59               (18) 08/18/2023 Common Stock 14,476   14,476 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Furlow Brenda S.
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN 55413
      SVP - General Counsel  

Signatures

 /s/ Anna Weispfenning as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed.   07/13/2020
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020.
(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.6400 to $271.5000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.8500 to $272.8300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.8500 to $273.7900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.3100 to $275.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.4000 to $276.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.6500 to $277.6200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.7700 to $278.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(9) Vests 2,500 share(s) on 07-Aug-2016, 2,500 share(s) on 07-Aug-2017, 2,500 share(s) on 07-Aug-2018, 1,579 share(s) on 07-Aug-2019
(10) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(11) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(12) Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)
(13) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(14) Fully exercisable
(15) Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023.
(16) Options to purchase 2,447 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 2,446 shares vest on each of 8/8/2021 and 8/8/2022.
(17) Options to purchase 3,167 shares vest on each of 8/9/2018 and 8/9/2019 and options to purchase 3,168 shares vest on each of 8/9/2020 and 8/9/2021.
(18) Options to purchase 3,619 shares vest on each of 8/18/2017, 8/18/2018, 8/18/2019 and 8/18/2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.